Efficacy of Sofosbuvir Combination Therapy for Hepatitis C Genotype 2 or 3 That Are Difficult to Manage with Standard Treatment

Young Kul Jung; Ju Hyun Kim

doi:10.4166/kjg.2013.62.3.185

Journal List > Korean J Gastroenterol > v.62(3) > 1007140

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Jung and Kim: Efficacy of Sofosbuvir Combination Therapy for Hepatitis C Genotype 2 or 3 That Are Difficult to Manage with Standard Treatment

Research Update

Korean J Gastroenterol 2013;62(3):185-187.

Published online: 4 October 2013

DOI: https://doi.org/10.4166/kjg.2013.62.3.185

Efficacy of Sofosbuvir Combination Therapy for Hepatitis C Genotype 2 or 3 That Are Difficult to Manage with Standard Treatment

Young Kul Jung, Ju Hyun Kim

Division of Gastroenterology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea

Correspondence to: Ju Hyun Kim, Division of Gastroenterology, Department of Internal Medicine, Gachon University Gil Medical Center, 21 Namdong-daero 774beon-gil, Namdong-gu, Incheon 405-760, Korea. Tel: +82-32-460-8201, Fax: +82-32-460-3408, E-mail: jhkim@gilhospital.com

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options (N Engl J Med 2013;368:1867–1877)

References

1. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatmentnaive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013; 381:2100–2107.

2. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013; 368:34–44.

3. Jacobson IM, Gordon SC, Kowdley KV, et al. POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013; 368:1867–1877.

4. Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49:1335–1374.

5. Park SY, Rim MY, Yo IK, et al. Efficacy of peginterferon and ribavirin combination therapy of chronic hepatitis C: a pooled analysis. Korean J Gastroenterol. 2012; 60:306–314.

6. Poordad F, McCone J Jr, Bacon BR, et al. SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364:1195–1206.

7. Jacobson IM, McHutchison JG, Dusheiko G, et al. ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364:2405–2416.

8. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatmentnaive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013; 13:401–408.

9. Jung YK, Kim JH, Ahn SM, et al. Role of interleukin 28b-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans. J Clin Gastroenterol. 2013; 47:644–650.

TOOLS

Similar articles